{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T02:45:48Z","timestamp":1788749148803,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016220","name":"Georgia Clinical and Translational Science Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jad.2025.119414","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T23:21:46Z","timestamp":1747351306000},"page":"119414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial"],"prefix":"10.1016","volume":"385","author":[{"given":"Brandan K.","family":"Penaluna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Vande Voort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Bobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Pazdernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Achtyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando S.","family":"Goes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Greden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar V.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.119414_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2018.05.005","article-title":"Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders","volume":"238","author":"Ahmed","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.jad.2025.119414_bb0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41386-020-00943-x","article-title":"Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings","volume":"46","author":"Athreya","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.jad.2025.119414_bb0015","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/da.22505","article-title":"Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice","volume":"33","author":"Bobo","year":"2016","journal-title":"Depress. Anxiety"},{"issue":"8","key":"10.1016\/j.jad.2025.119414_bb0020","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17512433.2022.2112949","article-title":"Machine learning, pharmacogenomics, and clinical psychiatry: predicting antidepressant response in patients with major depressive disorder","volume":"15","author":"Bobo","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jad.2025.119414_bb0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/pgs-2019-0157","article-title":"The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis","volume":"21","author":"Brown","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.jad.2025.119414_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Hum. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2025.119414_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.119414_bb0040","first-page":"33","article-title":"Ketamine for treatment of mood disorders and suicidality: a narrative review of recent progress","volume":"34","author":"Kritzer","year":"2022","journal-title":"Ann. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2025.119414_bb0045","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"issue":"4","key":"10.1016\/j.jad.2025.119414_bb0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bdi.13412","article-title":"Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: a systematic review","volume":"26","author":"Kumar","year":"2024","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2025.119414_bb0055","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2022.11.090","article-title":"Patients\u2019 recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression","volume":"323","author":"Lapidos","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.jad.2025.119414_bb0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40265-017-0702-8","article-title":"Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression","volume":"77","author":"Lener","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2025.119414_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115858","article-title":"Predicting non-response to ketamine for depression: an exploratory symptom-level analysis of real-world data among military veterans","volume":"335","author":"Miller","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.119414_bb0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119414_bb0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jad.2023.11.008","article-title":"National Network of depression centers position statement: insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder","volume":"346","author":"Niciu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.jad.2025.119414_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13121672","article-title":"An update on the efficacy of single and serial intravenous ketamine infusions and esketamine for bipolar depression: a systematic review and meta-analysis","volume":"13","author":"Nunez","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.jad.2025.119414_bb0085","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2022.10.003","article-title":"Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns","volume":"320","author":"Oliva","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119414_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jad.2023.12.033","article-title":"Clinical outcomes in the biomarkers of ketamine (bio-K) study of open-label IV ketamine for refractory depression","volume":"348","author":"Parikh","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119414_bb0095","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jad.2024.01.003","article-title":"Hypersomnia as a predictor of response to intravenous ketamine\/intranasal esketamine in treatment resistant depression","volume":"349","author":"Patarroyo-Rodriguez","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119414_bb0100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jad.2016.10.026","article-title":"Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion","volume":"208","author":"Pennybaker","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2025.119414_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/mpr.1388","article-title":"The structure of the Montgomery-Asberg depression rating scale over the course of treatment for depression","volume":"22","author":"Quilty","year":"2013","journal-title":"Int. J. Methods Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.jad.2025.119414_bb0110","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0269881113478283","article-title":"Serial infusions of low-dose ketamine for major depression","volume":"27","author":"Rasmussen","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2025.119414_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0253-7176.70510","article-title":"Depression: the disorder and the burden","volume":"32","author":"Reddy","year":"2010","journal-title":"Indian J. Psychol. Med."},{"issue":"4","key":"10.1016\/j.jad.2025.119414_bb0120","doi-asserted-by":"crossref","DOI":"10.1177\/02698811241238284","article-title":"Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression","volume":"38","author":"Rodrigues","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119414_bb0125","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health","author":"SAMHSA","year":"2022"},{"key":"10.1016\/j.jad.2025.119414_bb0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jad.2024.03.137","article-title":"Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-analysis","volume":"356","author":"Seshadri","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2025.119414_bb0135","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2025.119414_bb0140","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.biopsych.2022.10.007","article-title":"Ketamine-associated change in anhedonia and mTOR expression in treatment-resistant depression","volume":"93","author":"Singh","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.119414_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115829","article-title":"Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: the Bio-K multicenter trial","volume":"335","author":"Singh","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.119414_bb0150","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2024.01.262","article-title":"Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine\/esketamine","volume":"351","author":"Singh","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2025.119414_bb0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/da.20058","article-title":"A three-factor model of the MADRS in major depressive disorder","volume":"21","author":"Suzuki","year":"2005","journal-title":"Depress. Anxiety"},{"issue":"1","key":"10.1016\/j.jad.2025.119414_bb0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.119414_bb0165","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0033291711001905","article-title":"Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms","volume":"42","author":"Uher","year":"2012","journal-title":"Psychol. Med."},{"issue":"2\u20133","key":"10.1016\/j.jad.2025.119414_bb0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jad.2006.02.011","article-title":"Clinical relevance of depressive symptom improvement in bipolar I depressed patients","volume":"92","author":"Williamson","year":"2006","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119414_bb0175","author":"World Health Organization"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725008407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725008407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:04:00Z","timestamp":1749099840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725008407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"alternative-id":["S0165032725008407"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.119414","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.119414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119414"}}